Prostatic Neoplasms Clinical Trials in Boston, Massachusetts

5 studies are recruiting for prostatic neoplasms in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center ( Site 0043), Boston, Massachusetts

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. Prostate Active Surveillance Study

   The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This …

   Stage

   Not phased

   Ages

   21 and older

   Site

   Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts

   Locations

   11 in total

   Run by

   University of Washington

   See if you can join NCT00756665 on ClinicalTrials.gov

3. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

   The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   10 in total

   Run by

   Flare Therapeutics Inc.

   See if you can join NCT07719361 on ClinicalTrials.gov

4. RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

   This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT05765500 on ClinicalTrials.gov

5. Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

   The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance. The name of the study intervention involved in th…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   4 in total

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT05918263 on ClinicalTrials.gov